A multi-ancestry genome-wide association study meta-analysis uncovered 86 genetic loci associated with prostate cancer risk that researchers bundled into a genetic risk score.
At the Association for Molecular Pathology annual meeting, cancer researcher William Hahn talked about efforts to map cancer fitness genes at the genome scale.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.
Researchers built a systematic map of protein-drug interactions to investigate the behaviors of cancer cells and the dependencies of treatment responses.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
